We're always out and about THE FLU IS NOT ON OUR SCHEDULE We're always out and about.

WE STAND STRONG AGAINST THE FLU WITH AFLURIA

Exams are coming up THE FLU IS NOT ON MY SCHEDULE Exams are coming up.

I STAND STRONG AGAINST THE FLU WITH AFLURIA

I am really busy at work THE FLU IS NOT ON MY SCHEDULE I am really busy at work.

I STAND STRONG AGAINST THE FLU WITH AFLURIA

College keeps me busy enough THE FLU IS NOT ON OUR SCHEDULE College keeps me busy enough.

WE STAND STRONG AGAINST THE FLU WITH AFLURIA

We love to travel THE FLU IS NOT ON OUR SCHEDULE We love to travel.

WE STAND STRONG AGAINST THE FLU WITH AFLURIA

seqirus

The product information presented on this site is for U.S. residents only. Afluria® Quadrivalent, Afluria®, and Seqirus are trademarks of Seqirus UK Limited or its affiliates. PharmaJet® and Stratis® are registered trademarks of PharmaJet Inc. Manufactured by: Seqirus Pty Ltd Parkville, Victoria, 3052, Australia Distributed by: Seqirus USA Inc. 25 Deforest Avenue, Summit, NJ 07901, USA © 2017 Seqirus USA Inc. www.seqirus-us.com MCC Code, Month 2017

AFLURIA® QUADRIVALENT (INFLUENZA VACCINE) IMPORTANT SAFETY INFORMATION FOR CONSUMERS

What is Afluria® Quadrivalent Influenza Vaccine?

Afluria Quadrivalent is an inactivated (virus is not alive) influenza vaccine used for immunization against influenza disease caused by influenza virus subtypes A and B present in the vaccine. Afluria Quadrivalent cannot give you the flu. It stimulates the immune system to produce antibodies that can help to protect against influenza; the full effect of the vaccine is generally achieved approximately three weeks after receiving your vaccination. Annual vaccination is recommended against influenza.

Who should receive Afluria Quadrivalent?

Afluria Quadrivalent is approved for use in persons 5 years of age and older. Afluria Quadrivalent administered by needle and syringe can be used in patients 5 years of age and older. Afluria Quadrivalent can be used with the PharmaJet® Stratis® Needle‐Free Injection System in patients 18 through 64 years of age.

Who should not receive Afluria Quadrivalent?

Do not receive Afluria Quadrivalent if you have an egg allergy. Talk with your doctor if you have ever had a severe allergic reaction after receiving a flu vaccine. Talk with your doctor if you have ever had Guillain‐Barré Syndrome (GBS). Talk with your doctor if you get infections easily, are pregnant, or nursing.

What are the side effects of Afluria Quadrivalent?

The most common injection‐related adverse reactions in children (5 through 8 years of age) administered Afluria Quadrivalent with needle and syringe were pain, redness, and swelling. The most common side effect was headache.

The most common injection‐related adverse reactions in children (9 through 17 years of age) administered Afluria Quadrivalent with needle and syringe were pain, redness, and swelling. The most common side effects were headache, muscle pain, feeling tired and sick.

The most common injection‐related adverse reactions in adults (18 through 64) administered Afluria Quadrivalent with needle and syringe was pain. The most common side effects in adults were headache, muscle pain.

In adults age 65 and older, when administered Afluria Quadrivalent by needle and syringe, the most common injection‐related adverse reactions was pain. The most common side effect was muscle pain.

The most common injection‐related adverse reactions in adults (18 through 64) administered Afluria Quadrivalent by the PharmaJet Stratis Needle‐Free Injection System up to 7 days after vaccination were tenderness, swelling, pain, redness, itching, and bruising. The most common side effects were muscle pain, feeling tired and sick, and headache.

What do I do if I have side effects?

Report any severe or unusual side effects to your healthcare provider.
Please see the full prescribing information for Afluria Quadrivalent for further information.
To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc. at 1‐855‐358‐8966 or VAERS at 1‐800‐822‐7967 or www.vaers.hhs.gov.

You are also encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1‐800‐FDA‐1088.

Please, see accompanying US full Prescribing Information for AFLURIA QUADRIVALENT. The information provided here is not comprehensive. To learn more, talk about Afluria Quadrivalent with your healthcare provider or pharmacist.

AFLURIA® QUADRIVALENT is a trademark of Seqirus UK Limited and its affiliates. PHARMAJET and STRATIS are trademarks of Pharmajet, Inc.


AFLURIA® (Influenza Vaccine) Important Safety Information for Consumers

What is Afluria® Influenza Vaccine?

Afluria is an inactivated (virus is not alive) influenza vaccine used for immunization against influenza disease caused by influenza virus subtypes A and B present in the vaccine.
Afluria cannot give you the flu. It stimulates the immune system to produce antibodies that can help to protect against influenza; the full effect of the vaccine is generally achieved approximately three weeks after receiving your vaccination. Annual vaccination is recommended against influenza.

Who should receive Afluria?

Afluria administered by needle and syringe can be used in patients 5 years of age and older.
Afluria can be used with the PharmaJet® Stratis® Needle‐Free Injection System in patients 18 through 64 years of age.

Who should not receive Afluria?

Do not receive Afluria if you have an egg allergy. Talk with your doctor if you have ever had a severe allergic reaction after receiving a flu vaccine. Talk with your doctor if you have ever had Guillain‐Barré Syndrome (GBS).
Talk with your doctor if you get infections easily, are pregnant, or nursing.

What are the side effects of Afluria?

Fever side effects were observed in children 5 through 8 years of age in 2010.

The most common injection‐related adverse reactions in children (5 through 17 years of age) administered Afluria with needle and syringe were pain, redness, and swelling. The most common side effects were headache, muscle pain, irritability, feeling tired and sick, and fever.

The most common injection‐related adverse reactions in adults (18 through 64) administered Afluria with needle and syringe were tenderness, pain, swelling, redness, and itching. The most common side effects in adults were muscle aches, headache, and feeling tired and sick.

The most common injection‐related adverse reactions in adults (18 through 64) administered Afluria by the PharmaJet Stratis Needle‐Free Injection System up to 7 days after vaccination were tenderness, swelling, pain, redness, itching, and bruising. The most common side effects were muscle pain, feeling tired and sick, and headache.

In adults age 65 and older, when administered Afluria by needle and syringe, the most common injection‐related adverse reactions were tenderness and pain.

What do I do if I have side effects?

Report any severe or unusual side effects to your healthcare provider. Please see the full prescribing information for Afluria for further information. To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc. at 1-855-358-8966 or VAERS at 1‐800‐822‐7967 or www.vaers.hhs.gov.

You are also encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1‐800‐FDA‐1088.

The information provided here is not comprehensive. To learn more, talk about Afluria with your healthcare provider or pharmacist. The FDA‐approved product labeling can be found at http://www.afluria.com/prescribing-information.aspx or 1-855-358-8966.

AFLURIA is a registered trademark of Seqirus UK Limited or its affiliates.

PHARMAJET and STRATIS are registered trademarks of PharmaJet.